MoonLake Immunotherapeutics (MLTX)
NASDAQ: MLTX · Real-Time Price · USD
36.35
-2.72 (-6.96%)
Apr 1, 2025, 4:00 PM EDT - Market closed
Company Description
MoonLake Immunotherapeutics, a clinical stage biopharmaceutical company, engages in developing therapies.
The company develops Sonelokimab, a novel tri-specific investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis.
MoonLake Immunotherapeutics was founded in 2021 and is headquartered in Zug, Switzerland.
MoonLake Immunotherapeutics
Country | Switzerland |
Founded | 2021 |
Industry | Biotechnology |
Sector | Healthcare |
Employees | 100 |
CEO | Jorge da Silva |
Contact Details
Address: Dorfstrasse 29 Zug, 6300 Switzerland | |
Phone | 41 415108022 |
Website | moonlaketx.com |
Stock Details
Ticker Symbol | MLTX |
Exchange | NASDAQ |
Share Class | Class A Shares |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001821586 |
CUSIP Number | 61559X104 |
ISIN Number | KY61559X1045 |
SIC Code | 2834 |
Key Executives
Name | Position |
---|---|
Dr. Jorge Santos da Silva | Co-Founder, Chief Executive Officer and Director |
Dr. Kristian Reich | Co-Founder and Chief Scientific Officer |
Matthias Bodenstedt | Chief Financial Officer |
Oliver Daltrop Ph.D. | Chief Operations Officer |
Carla Bretes | Director Investor Relations and Business Development |
Nicolas Mosimann | General Counsel |
Joana Cortez | Senior Director Legal and Compliance |
Tino Anthamatten | Vice President of Marketing, Market Access and Pricing |
Luciana Marques | Director of Human Resources, People and Culture |
Nuala Brennan | Chief Clinical Development Officer |
Latest SEC Filings
Date | Type | Title |
---|---|---|
Feb 26, 2025 | 10-K | Annual Report |
Feb 26, 2025 | 8-K | Current Report |
Feb 14, 2025 | SCHEDULE 13G | Filing |
Feb 12, 2025 | SCHEDULE 13G/A | Filing |
Dec 18, 2024 | 8-K | Current Report |
Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
Nov 7, 2024 | 10-Q | Quarterly Report |
Nov 7, 2024 | 8-K | Current Report |
Oct 8, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
Sep 11, 2024 | 8-K | Current Report |